Apo A-I modulating therapies

Current Cardiology Reports

Volumn 13, Issue 6, 2011, Pages 537-543

  Nicholls, Stephen J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Apolipoprotein A I; Atherosclerosis; Coronary artery disease; High density lipoproteins; Lipids; Risk factors

Indexed keywords

AGENTS AFFECTING PROTEIN METABOLISM; APOLIPOPROTEIN A1; ETC 216; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEPTIDOMIMETIC AGENT; PLACEBO; RVX 208; TORCETRAPIB; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG RESPONSE; DRUG TARGETING; FAMILIAL HYPERCHOLESTEROLEMIA; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE MODIFICATION; LIPID COMPOSITION; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS REGULATION; TREATMENT OUTCOME;

ANIMALS; APOLIPOPROTEIN A-I; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HUMANS; HYPOLIPIDEMIC AGENTS; RISK FACTORS;

EID: 81255158515     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-011-0223-0     Document Type: Article

References (49)

1. T Vaisar S Pennathur PS Green, et al. 2007 Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL J Clin Invest 117 746 756 17332893 10.1172/JCI26206 1:CAS:528: DC%2BD2sXis12htLs%3D This paper characterizes a substantial number of proteins carried on HDL particles
2. DP Barr EM Russ HA Eder 1951 Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions Am J Med 11 480 493 14885223 10.1016/0002-9343(51)90183-0 1:STN:280:DyaG38%2FhsFegsQ%3D%3D
3. T Gordon WP Castelli MC Hjortland WB Kannel TR Dawber 1977 High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am J Med 62 707 714 193398 10.1016/0002-9343(77)90874-9 1:CAS:528:DyaE2sXhvVOhtbg%3D
4. P Barter AM Gotto JC LaRosa, et al. 2007 HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 1301 1310 17898099 10.1056/NEJMoa064278 1:CAS:528:DC%2BD2sXhtFSmtr3M This paper highlights the importance of a low HDL cholesterol in patients with very low levels of LDL cholesterol
5. JJ Badimon L Badimon A Galvez R Dische V Fuster 1989 High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits Lab Invest 60 455 461 2927083 1:CAS:528:DyaL1MXhvFShurk%3D
6. JJ Badimon L Badimon V Fuster 1990 Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit J Clin Invest 85 1234 1241 2318976 10.1172/JCI114558 1:CAS:528:DyaK3cXitlehtbw%3D
7. AS Plump CJ Scott JL Breslow 1994 Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse Proc Nat Acad Sci USA 91 9607 9611 7937814 10.1073/pnas.91.20.9607 1:CAS:528:DyaK2cXmt1Okur0%3D
8. EM Rubin RM Krauss EA Spangler JG Verstuyft SM Clift 1991 Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI Nature 353 265 267 1910153 10.1038/353265a0 1:CAS:528:DyaK3MXmtVKrsL0%3D
9. S Ameli A Hultgardh-Nilsson B Cercek, et al. 1994 Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits Circulation 90 1935 1941 7923682 1:CAS:528:DyaK2MXhvFOgsbo%3D
10. SJ Nicholls B Cutri SG Worthley, et al. 2005 Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits Arterioscler Thromb Vasc Biol 25 2416 2421 16141405 10.1161/01.ATV.0000184760.95957.d6 1:CAS:528:DC%2BD2MXhtFCisbbK
11. JX Rong J Li ED Reis, et al. 2001 Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content Circulation 104 2447 2452 11705823 10.1161/hc4501.098952 1:CAS:528: DC%2BD3MXpt1KhsL8%3D
12. PK Shah J Yano O Reyes, et al. 2001 High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice Circulation 103 3047 3050 11425766 10.1161/hc2501.092494 1:CAS:528:DC%2BD3MXlsFyhsLs%3D
13. HB Brewer Jr 2007 HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease Curr Cardiol Rep 9 486 492 17999874 10.1007/BF02938393
14. PJ Barter S Nicholls KA Rye GM Anantharamaiah M Navab AM Fogelman 2004 Antiinflammatory properties of HDL Circ Res 95 764 772 15486323 10.1161/01.RES.0000146094.59640.13 1:CAS:528:DC%2BD2cXot1aitrY%3D
15. PW Shaul C Mineo 2004 HDL action on the vascular wall: is the answer NO? J Clin Invest 113 509 513 14966559 1:CAS:528:DC%2BD2cXhsFKhsLc%3D
16. SJ Nicholls GJ Dusting B Cutri, et al. 2005 Reconstituted high density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits Circulation 111 1543 1550 15781735 10.1161/01.CIR.0000159351.95399.50 1:CAS:528: DC%2BD2MXisVGrtL4%3D
17. WE Kraus JA Houmard BD Duscha, et al. 2002 Effects of the amount and intensity of exercise on plasma lipoproteins N Engl J Med 347 1483 1492 12421890 10.1056/NEJMoa020194 1:CAS:528:DC%2BD38XosVOnsL8%3D
18. SJ Nicholls EM Tuzcu I Sipahi, et al. 2007 Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis JAMA 297 499 508 17284700 10.1001/jama.297.5.499 1:CAS:528:DC%2BD2sXhs1Wis7k%3D This paper highlights the importance of small increases in HDL cholesterol in predicting statin effects on plaque
19. Y Cui DJ Watson CJ Girman, et al. 2009 Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study) Am J Cardiol 104 829 834 19733719 10.1016/j.amjcard.2009.05.020 1:CAS:528:DC%2BD1MXhtV2rt7%2FE
20. VG Athyros DP Mikhailidis AA Papageorgiou, et al. 2004 Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study Curr Med Res Opin 20 627 637 15171226 10.1185/030079904125003421 1:CAS:528:DC%2BD2cXltFyntrk%3D
21. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 375:1875-84.
22. BG Brown X-Q Zhao A Chait, et al. 2001 Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 1583 1592 11757504 10.1056/NEJMoa011090 1:CAS:528: DC%2BD3MXoslyhsLs%3D
23. AJ Taylor TC Villines EJ Stanek, et al. 2009 Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 2113 2122 19915217 10.1056/NEJMoa0907569 1:CAS:528:DC%2BD1MXhsFSnsLzP
24. PL Canner KG Berge NK Wenger, et al. 1986 Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol 8 1245 1255 3782631 10.1016/S0735-1097(86)80293-5 1:STN:280: DyaL2s%2FlvVCqtQ%3D%3D
25. PJ Barter MJ Chapman CH Hennekens DJ Rader AR Tall 2003 Cholesteryl ester transfer protein. A novel target for raising HDL and inhibiting atherosclerosis Arterioscler Thromb Vasc Biol 23 160 167 12588754 10.1161/01.ATV.0000054658. 91146.64 1:CAS:528:DC%2BD3sXptF2jsw%3D%3D
26. PJ Barter M Caulfield M Eriksson, et al. 2007 Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2109 2122 17984165 10.1056/NEJMoa0706628 1:CAS:528:DC%2BD2sXhtlGns7bL
27. SE Nissen JC Tardif SJ Nicholls, et al. 2007 Effect of torcetrapib on the progression of coronary atherosclerosis N Engl J Med 356 1304 1316 17387129 10.1056/NEJMoa070635 1:CAS:528:DC%2BD2sXjsFGnsrY%3D
28. ML Bots FL Visseren GW Evans, et al. 2007 Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial Lancet 370 153 160 17630038 10.1016/S0140-6736(07)61088-5 1:CAS:528:DC%2BD2sXns12jtLg%3D
29. JJ Kastelein SI van Leuven L Burgess, et al. 2007 Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N Engl J Med 356 1620 1630 17387131 10.1056/NEJMoa071359 1:CAS:528:DC%2BD2sXksFCmsb4%3D
30. M Vergeer ES Stroes 2009 The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors Am J Cardiol 104 32E 38E 19895942 10.1016/j.amjcard.2009.09.017 1:CAS:528:DC%2BD1MXhs1Wju7rJ
31. L Yvan-Charvet F Matsuura N Wang, et al. 2007 Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL Arterioscler Thromb Vasc Biol 27 1132 1138 17322101 10.1161/ATVBAHA.106.138347 1:CAS:528:DC%2BD2sXktFagtLs%3D
32. SJ Nicholls EM Tuzcu DM Brennan JC Tardif SE Nissen 2008 Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) Circulation 118 2506 2514 19029466 10.1161/CIRCULATIONAHA.108.790733 1:CAS:528:DC%2BD1cXhsVerur3L
33. B Angelin P Parini M Eriksson 2002 Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDL Atheroscler Suppl 3 23 30 12573360 10.1016/S1567-5688(02)00047-8 1:CAS:528:DC%2BD3sXotlCguw%3D%3D
34. RJ Bisoendial GK Hovingh JHM Levels, et al. 2003 Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein Circulation 107 2944 2948 12771001 10.1161/01.CIR.0000070934.69310.1A
35. LE Spieker I Sudano D Hurlimann, et al. 2002 High-density lipoprotein restores endothelial function in hypercholesterolemic men Circulation 105 1399 1402 11914243 10.1161/01.CIR.0000013424.28206.8F 1:CAS:528:DC%2BD38XjsVyrtb4%3D
36. SI van Leuven RS Birjmohun R Franssen, et al. 2009 ApoAI- phosphatidylcholine infusion neutralizes the atherothrombotic effects of C-reactive protein in humans J Thromb Haemost 7 347 354 18983488 10.1111/j.1538-7836.2008.03175.x
37. SE Nissen T Tsunoda EM Tuzcu, et al. 2003 Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial JAMA 290 2292 2300 14600188 10.1001/jama.290.17.2292 1:CAS:528:DC%2BD3sXovVCjtbc%3D
38. SJ Nicholls K Uno Y Kataoka SE Nissen 2011 ETC-216 for coronary artery disease Expert Opin Biol Ther 11 387 394 21271950 10.1517/14712598.2011.557061 1:CAS:528:DC%2BC3MXhs1yksr0%3D
39. SJ Nicholls EM Tuzcu I Sipahi, et al. 2006 Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano J Am Coll Cardiol 47 992 997 16516083 10.1016/j.jacc.2005.11.040 1:CAS:528:DC%2BD28XitVaruro%3D
40. CR Sirtori L Calabresi G Franceschini, et al. 2001 Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study Circulation 103 1949 1954 11306522 1:CAS:528:DC%2BD3MXjslKksL8%3D
41. JC Tardif J Gregoire PL L'Allier, et al. 2007 Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial JAMA 297 1675 1682 17387133 10.1001/jama.297.15.jpc70004
42. R Waksman R Torguson KM Kent, et al. 2010 A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome J Am Coll Cardiol 55 2727 2735 20538165 10.1016/j.jacc.2009. 12.067 This paper shows evidence that delipidated HDL promotes regression of coronary atherosclerosis
43. Bailey D, Jahagirdar R, Gordon A, et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol. 55:2580-9.
44. SJ Nicholls A Gordon J Johansson, et al. 2011 Efficacy and safety of a novel oral inducer of apolipoprotein A-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial J Am Coll Cardiol 57 1111 1119 21255957 10.1016/j.jacc.2010.11.015 1:CAS:528: DC%2BC3MXkslWntLc%3D
45. Sherman CB, Peterson SJ, Frishman WH. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol Rev. 18:141-7.
46. CE Watson N Weissbach L Kjems, et al. 2011 Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function J Lipid Res 52 361 373 21068008 10.1194/jlr.M011098 1:CAS:528:DC%2BC3MXht1alu70%3D
47. T Bhattacharyya SJ Nicholls EJ Topol, et al. 2008 Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk JAMA 299 1265 1276 18349088 10.1001/jama.299.11.1265 1:CAS:528:DC%2BD1cXjsVOmtb8%3D
48. SJ Nicholls L Zheng SL Hazen 2005 Formation of dysfunctional high-density lipoprotein by myeloperoxidase Trends Cardiovasc Med 15 212 219 16182131 10.1016/j.tcm.2005.06.004 1:CAS:528:DC%2BD2MXhtVart7vN
49. Wang Z, Nicholls SJ, Rodriguez ER, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med. 2007.